TABLE 1.
Patient characteristics
| Characteristica | Value for group |
|
|---|---|---|
| COVID-19 (n = 83) | Non-COVID (n = 13) | |
| Gender [no. (%)] | ||
| Female | 39 (47) | 4 (31) |
| Male | 44 (53) | 9 (69) |
| Race/ethnicity [no. (%)] | ||
| Black | 56 (67) | 7 (54) |
| White | 20 (24) | 6 (46) |
| Asian | 3 (4) | 0 |
| Other/unknown | 4 (5) | 0 |
| Hispanic/Latinx | 0 | 1 (8) |
| Age | ||
| Median (min, max) | 64 (36–91) | 60 (39–94) |
| BMI | ||
| Median (min, max) | 29.8 (17–62) | 23.0 (19–31) |
| No. (%) with preexisting comorbidity | ||
| Diabetes | 39 (47) | 6 (46) |
| Hypertension | 67 (81) | 7 (54) |
| Coronary artery disease | 16 (19) | 3 (23) |
| Stroke | 17 (20) | 2 (15) |
| Chronic lung disease | 34 (41) | 5 (38) |
| Renal disease (≥stage 4) | 15 (18) | 3 (23) |
| Cancer (within 6 mo) | 10 (12) | 4 (31) |
| HIV infection | 3 (4) | 0 |
| Organ transplant | 5 (6) | 1 (8) |
| Immunosuppressive therapy | 12 (14) | 3 (23) |
| BMI ≥35 | 27 (33) | 0 |
| Any major comorbidity | 78 (94) | 13 (100) |
| No. (%) receiving treatment | ||
| Corticosteroids | 52 (63) | |
| Remdesivir | 18 (22) | |
| Hydroxychloroquine | 39 (47) | |
| Convalescent-phase plasma | 4 (5) | |
| Antibacterials | 72 (87) | 13 (100) |
| Antifungals | 20 (24) | 5 (38) |
| Mechanical ventilation | 40 (48) | 8 (62) |
| ECMO | 5 (6) | 1 (8) |
| No. (%) with maximum WHO score (example) | ||
| 4 (no supplemental O2) | 20 (24) | |
| 5 (low-flow O2) | 8 (10) | |
| 6 (high-flow O2) | 7 (8) | |
| 7 (intubated) | 2 (2) | |
| 8 (intubated, low P/F; vasopressors) | 14 (17) | |
| 9 (ECMO; pressors; dialysis) | 12 (14) | |
| 10 (death) | 20 (24) | 6 (46) |
a
BMI, body mass index; ECMO, extracorporeal membrane oxygenation; P/F, ratio of PaO2 to FiO2.